ASND vs AZN: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AZN is the larger of the two ($289.34B market cap): the incumbent the market prices for continued execution (16.49x forward earnings, beta 0.16). ASND is the smaller challenger ($17.03B), actually pricier on forward earnings (25.89x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ASND vs AZN: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ASND | AZN | What it tells you |
|---|---|---|---|
| Market cap | $17.03B | $289.34B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 25.89 | 16.49 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 19.83 | 26.39 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Price vs 52-week range | 75% of range | 56% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 10.53 | 5.59 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: AZN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ASND and AZN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASND and AZN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASND and AZN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Ascendis Pharma (ASND) do?
Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. The business is built on TransCon, a prodrug technology that attaches a known parent drug to a carrier through a linker that releases the active molecule slowly and predictably, which lets Ascendis convert daily injections into weekly or monthly dosing. Three products are approved and marketed: SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) for adult hypoparathyroidism, and YUVIWEL (navepegritide, developed as TransCon CNP), which received accelerated FDA approval with orphan exclusivity in May 2026 for pediatric achondroplasia. On October 16, 2026 the European Medicines Agency's CHMP issued a positive opinion recommending TransCon CNP for children with achondroplasia, the step that normally precedes a European Commission decision. Trailing twelve month revenue is roughly EUR 1.05 billion, with gross margin near 91 percent.
What does AstraZeneca (AZN) do?
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.
ASND vs AZN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ASND drivers: YORVIPATH is carrying the model; YUVIWEL opens a second large launch.
- AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. For AZN, the dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time.
ASND or AZN: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ASND if you believe its drivers more; AZN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASND and AZN guides.
ASND vs AZN: the full fundamentals
ASND. The trailing earnings multiple is the number most likely to mislead here, because trailing net income is driven largely by the roughly EUR 679 million deferred tax asset recognized in the first quarter of 2026, not by operations. Price to sales near 14x and forward price to earnings near 21x are the cleaner framing, and both price in continued rapid growth; consensus calls for third-quarter revenue of about EUR 367 million. The mean analyst target of about $307 across 21 analysts sits well above the $226 share price.
AZN. AstraZeneca trades at about 25 times trailing reported earnings but about 14.6 times forward earnings, a gap that reflects heavy amortisation and one-off charges in reported profit and consensus for 2026 core EPS near $10.05 rising to about $11.34 in 2027. After falling about 9.5% in 2026, the forward multiple sits near the low end of where a growth-oriented large-cap pharma usually trades, so the valuation now reflects more caution about the 2032 patent cliff than enthusiasm for the $80 billion 2030 goal. Q3 2026 results arrive October 30, with consensus revenue near $16.0 billion. Figures are approximate and tied to the asOf date; confirm live numbers before acting.
Headline figures (approximate, October 2026): ASND shows market cap ~$14.9 billion at ~$226 per share (Oct 16, 2026), revenue (ttm) ~EUR 1.05 billion; Q2 2026 ~EUR 340 million, up ~115%, q2 2026 eps 0.90 vs ~0.77 consensus, profitability Gross margin ~91%; TTM net income ~EUR 742 million, inflated by a ~EUR 679 million one-time tax asset; AZN shows revenue (ttm) About $61.4 billion; Q2 2026 revenue about $15.4 billion, up roughly 6% year over year, net income (ttm) About $10.5 billion, a net margin near 17%, with gross margin near 82%, eps Q2 2026 EPS $1.32 vs about $1.25 expected; trailing reported EPS about $6.69, p/e About 25x trailing reported earnings, about 14.6x forward.
The bottom line: ASND vs AZN
ASND and AZN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ASND and AZN exposure against your real portfolio. It is not an investment adviser.
Wondering how ASND or AZN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Ascendis Pharma
Ask Walnut's AI anything about ASND and see how it fits what you own.
FAQ
What is the difference between ASND and AZN?
+
Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ASND or AZN the better stock?
+
Neither is universally better. AZN is the larger incumbent; ASND is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ASND or AZN?
+
On forward P/E (as of November 2026), ASND trades at 25.89x and AZN at 16.49x, so AZN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ASND and AZN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ASND vs AZN?
+
ASND: Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. AstraZeneca's eneboparatide and other parathyroid hormone programs target the same indication, while BioMarin's Voxzogo is entrenched in achondroplasia and a long-acting successor is in development, and oral FGFR3 approaches could reframe the category entirely; in October 2026 the FDA granted priority review to BridgeBio's achondroplasia filing. YUVIWEL was cleared under accelerated approval, which carries confirmatory evidence obligations that can constrain or withdraw a label. Taking back TransCon Semaglutide moves the cost and risk of an obesity program, a field crowded with the largest drugmakers, onto Ascendis alone. UBS cut its price target to $269 from $307 in October 2026. Ascendis is a foreign private issuer that reports in euros and files Form 20-F, so currency translation and a lighter interim disclosure cadence than a domestic filer both apply. On the legal side, Ascendis is an appellant in patent litigation against BioMarin at the Federal Circuit (No. 26-1026), and plaintiffs' firms publicized securities class action investigation notices in 2023 following the FDA deficiency letter on TransCon PTH, though those solicitations are not the same as a filed complaint and no active securities-fraud class action was identified as of August 2026. AZN: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. Generic and biosimilar erosion is already visible, with first generics to Farxiga cleared in 2026. Pipeline risk is constant, since late-stage trial failures such as a disappointing AVANZAR result can erase billions in expected value quickly. China, about a tenth of revenue, carries added uncertainty after the company's former China head was indicted in a compliance case that drew investor lawsuits. Drug pricing policy, US tariffs and currency swings add further volatility, and the balance sheet carries about $32 billion of debt against about $5 billion of cash. As a large-cap pharma the stock can still fall sharply on a single disappointing readout or regulatory decision, as its roughly 22% slide from the 52-week high shows.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ASND or AZN; figures are approximate and dated (as of November 2026). Verify current data before investing.